Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Other Non-Current Liabilities (2022 - 2024)

Historic Other Non-Current Liabilities for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to $80.8 million.

  • Addex Therapeutics' Other Non-Current Liabilities rose 830.59% to $80.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.8 million, marking a year-over-year increase of 830.59%. This contributed to the annual value of $73.5 million for FY2024, which is 208.89% up from last year.
  • According to the latest figures from Q3 2025, Addex Therapeutics' Other Non-Current Liabilities is $80.8 million, which was up 830.59% from $78.1 million recorded in Q2 2025.
  • In the past 5 years, Addex Therapeutics' Other Non-Current Liabilities registered a high of $80.8 million during Q3 2025, and its lowest value of $66.9 million during Q3 2022.
  • Over the past 4 years, Addex Therapeutics' median Other Non-Current Liabilities value was $72.8 million (recorded in 2023), while the average stood at $72.8 million.
  • In the last 5 years, Addex Therapeutics' Other Non-Current Liabilities skyrocketed by 933.85% in 2023 and then crashed by 291.81% in 2025.
  • Addex Therapeutics' Other Non-Current Liabilities (Quarter) stood at $67.1 million in 2022, then rose by 8.61% to $72.8 million in 2023, then rose by 1.26% to $73.8 million in 2024, then increased by 9.51% to $80.8 million in 2025.
  • Its Other Non-Current Liabilities stands at $80.8 million for Q3 2025, versus $78.1 million for Q2 2025 and $71.9 million for Q1 2025.